IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients
IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients Karim Bouzakri 1 , Håkan K.R. Karlsson 1 , Henrik Vestergaard 2 , Sten Madsbad 3 , Erik Christiansen 4 and Juleen R. Zierath 1 1 Section of Integrative Physiology, Department of Molecular Medic...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 55; no. 3; pp. 785 - 791 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Alexandria, VA
American Diabetes Association
01.03.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients
Karim Bouzakri 1 ,
Håkan K.R. Karlsson 1 ,
Henrik Vestergaard 2 ,
Sten Madsbad 3 ,
Erik Christiansen 4 and
Juleen R. Zierath 1
1 Section of Integrative Physiology, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
2 Division of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
3 Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
4 Department of Medicine, Division of Endocrinology, Roskilde County Hospital, Copenhagen, Denmark
Address correspondence and reprint requests to Professor Juleen R. Zierath, Karolinska Institute, Department of Molecular
Medicine and Surgery, Section of Integrative Physiology, von Eulers väg 4, 4th floor, S-171 77 Stockholm, Sweden. E-mail:
juleen.zierath{at}ki.se
Abstract
Insulin-dependent diabetic recipients of successful pancreas allografts achieve self-regulatory insulin secretion and discontinue
exogenous insulin therapy; however, chronic hyperinsulinemia and impaired insulin sensitivity generally develop. To determine
whether insulin resistance is accompanied by altered signal transduction, skeletal muscle biopsies were obtained from pancreas-kidney
transplant recipients ( n = 4), nondiabetic kidney transplant recipients (receiving the same immunosuppressive drugs; n = 5), and healthy subjects ( n = 6) before and during a euglycemic-hyperinsulinemic clamp. Basal insulin receptor substrate (IRS)-1 Ser (312) and Ser (616)
phosphorylation, IRS-1–associated phosphatidylinositol 3-kinase activity, and extracellular signal–regulated kinase (ERK)-1/2
phosphorylation were elevated in pancreas-kidney transplant recipients, coincident with fasting hyperinsulinemia. Basal IRS-1
Ser (312) and Ser (616) phosphorylation was also increased in nondiabetic kidney transplant recipients. Insulin increased
phosphorylation of IRS-1 at Ser (312) but not Ser (616) in healthy subjects, with impairments noted in nondiabetic kidney
and pancreas-kidney transplant recipients. Insulin action on ERK-1/2 and Akt phosphorylation was impaired in pancreas-kidney
transplant recipients and was preserved in nondiabetic kidney transplant recipients. Importantly, insulin stimulation of the
Akt substrate AS160 was impaired in nondiabetic kidney and pancreas-kidney transplant recipients. In conclusion, peripheral
insulin resistance in pancreas-kidney transplant recipients may arise from a negative feedback regulation of the canonical
insulin-signaling cascade from excessive serine phosphorylation of IRS-1, possibly as a consequence of immunosuppressive therapy
and hyperinsulinemia.
ERK, extracellular signal–regulated kinase
IRS, insulin receptor substrate
MAPK, mitogen-activated protein kinase
NEFA, nonesterified free fatty acid
PI, phosphatidylinositol
Footnotes
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Accepted November 28, 2005.
Received June 22, 2005.
DIABETES |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/diabetes.55.03.06.db05-0796 |